目的 探究酚磺乙胺注射液聯(lián)合醋酸奧曲肽注射液治療肝硬化上消化道出血的臨床療效。方法 選取2011年3月-2016年6月中國人民解放軍白求恩國際和平醫(yī)院二五六臨床部消化內(nèi)科收治的肝硬化上消化道出血患者64例作為研究對象，在隨機(jī)分組的原則下將所有患者分為對照組和治療組，每組各32例。對照組靜脈滴注醋酸奧曲肽注射液，0.1 mg加入到0.9%氯化鈉溶液250 mL中，滴注速度0.025 mg/h，1次/d。治療組在對照組基礎(chǔ)上靜脈滴注酚磺乙胺注射液，0.5 g加入5%葡萄糖注射液250 mL中，2次/d。兩組患者均連續(xù)治療4 d。觀察兩組的臨床療效，比較兩組的臨床指標(biāo)、肝纖維化指標(biāo)和門靜脈血流量（PVF）。結(jié)果 治療后，對照組和治療組的總有效率分別為75.00%、96.88%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組止血時間、住院時間和輸血量均明顯低于對照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組人Ⅲ型前膠原（PCⅢ）、層粘連蛋白（LN）、PVF均顯著性降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 酚磺乙胺注射液聯(lián)合醋酸奧曲肽注射液治療肝硬化上消化道出血具有較好的臨床療效，可改善肝纖維化，縮短止血時間和住院時間，減少輸血量，降低門靜脈壓力，安全性較好，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Etamsylate Injection combined with Octreotide Acetate Injection in treatment of cirrhosis complicated with upper gastrointestinal hemorrhage. Methods Patients (64 cases) with cirrhosis complicated with upper gastrointestinal hemorrhage in Department of Gastroenterology of 256 Clinical Department of Bethune International Peace Hospital of People's Liberation Army from March 2011 to June 2016 were randomly divided into control and treatment groups, and each group had 32 cases. Patients in the control group were iv administered with Octreotide Acetate Injection, 0.1 mg added into 250 mL normal saline, infusion speed of 0.025 mg/h, once daily. Patients in the treatment group were iv administered with Etamsylate Injection on the basis of the control group, 0.5 g added into 5% glucose solution 250 mL, twice daily. Patients in two groups were treated for 4 d. After treatment, the clinical efficacies were evaluated, and clinical indexes, liver fibrosis, and PVF in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 75.00% and 96.88%, respectively, and there was difference between two groups (P<0.05). After treatment, hemostasis time, hospitalization time, and blood transfusion volume in the treatment group were significantly shorter than those in the group, and there was difference between two groups (P<0.05). After treatment, PCⅢ, LN, and PVF in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Etamsylate Injection combined with Octreotide Acetate Injection has clinical curative effect in treatment of cirrhosis complicated with upper gastrointestinal hemorrhage, can improve liver fibrosis, shorten hemostasis time and hospitalization time, decrease portal pressure, with good safety, which has a certain clinical application value.